Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04153292 · ClinicalTrials.gov registry record · NA

The ENCIRCLE Trial

A NA study of Mitral Regurgitation and Mitral Valve Insufficiency, sponsored by Edwards Lifesciences.

Recruiting
Registry status
NA
Development phase
900
Enrollment target
20
Study locations

NCT04153292: Recruiting NA study of Mitral Regurgitation and Mitral Valve Insufficiency, sponsored by Edwards Lifesciences.

NCT04153292 is a NA study of Mitral Regurgitation and Mitral Valve Insufficiency that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 900 participants, roughly in line with the 990-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04153292, a NA study of Mitral Regurgitation and Mitral Valve Insufficiency, is actively recruiting participants, sponsored by Edwards Lifesciences.

RECRUITING
Registry status
NA
Development phase
900 participants
Enrollment target
20
Study locations

Study Summary

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

Primary Outcome

Number of subjects with death and/or heart failure rehospitalization

Interventions

  • DEVICE SAPIEN M3 valve and dock

Study Locations (20)

California

  • Scripps Health - La Jolla
  • Good Samaritan Hospital - Los Angeles
  • Cedars-Sinai Medical Center - Los Angeles
  • Kaiser Sunset LA - Los Angeles
  • Saint Joseph Hospital - Orange
  • California Pacific Medical Center - San Francisco

Florida

  • Delray Medical Center - Delray Beach
  • Cardiac & Vascular Institute Foundation - Gainesville
  • Ascension St. Vincent's Hospital - Jacksonville
  • Naples Community Hospital - Naples
  • Sarasota Memorial Hospital - Sarasota

Arizona

  • Banner University Medical Center - Phoenix
  • Saint Josephs Hospital Medical Center Dignity Health - Phoenix
  • TMC Healthcare - Tucson

Georgia

  • Emory University - Atlanta
  • Piedmont Healthcare - Atlanta

Illinois

  • Rush University Medical Center - Chicago
  • Northshore University Health System - Glenview

Alabama

  • Heart Center Hospital - Huntsville

Colorado

  • UC Health Northern Colorado (Medical Center of the Rockies) - Loveland

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2020-11-12
Est. Completion 2031-02-28
Phase NA
Edwards Lifesciences

57 total trials

What NCT04153292 shows while recruiting

NCT04153292 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 990-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target.

The record links to 2 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which SAPIEN M3 valve and dock is the first listed.

NCT04153292 names 20 study sites across 7 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT04153292 about?

NCT04153292 is a clinical study titled "The ENCIRCLE Trial". This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be ...

What is the current status of trial NCT04153292?

This trial is currently recruiting. It is a NA study. The enrollment target is 900 participants. The study started on 2020-11-12. Estimated completion is 2031-02-28.

What conditions does trial NCT04153292 study?

This clinical trial studies the following conditions: Mitral Regurgitation, Mitral Valve Insufficiency.

What interventions are being tested in trial NCT04153292?

The interventions under investigation include: SAPIEN M3 valve and dock (DEVICE).

Who is sponsoring clinical trial NCT04153292?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04153292 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mitral Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04153292's enrollment target sits among peer trials

900 8th of 26 higher than 19 of 26 other Mitral Regurgitation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mitral Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

  • NCT02960022 · 900 participants · Phase 2

    A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04153292, the US trial registry maintained by the National Library of Medicine. NCT04153292 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.